Supplemental Table S1.

Clinical characteristics and outcomes of SOT recipients with COVID-19

who received tocilizumab versus non-matched controlsa

All (n=117) Tocilizumab group Non-tocilizumab p-value

(n=29) group (n=88)
Age in years 63 (49-70) 62 (48-69) 63 (49.5-70) 0.50
Male sex (%) 75 (64) 18 (62) 57 (65) 0.79
Race (%) 0.22
White 60 (51) 18 (62) 42 (48)
Black 31 (26) 7 (24) 24 (27)
Asian 3 (3) 1 (3) 2 (2)
Other 19 (16) 3 (10) 16 (18)
Hispanic Ethnicity (%) 55 (47) 12 (41) 43 (49) 0.48
Organ Transplant (%) 0.17
Kidney 57 (49) 15 (52) 42 (48)
Lung 24 (21) 5 (17) 19 (42)
Liver 10 (9) 1 (3) 9 (10)
Heart 18 (15) 6 (21) 12 (14)
Heart-kidney 4 (3) 2 (7) 1 (1)
Liver-kidney 2 (2) 0 (0) 2 (2)
Kidney-pancreas 2 (2) 0 (0) 2 (2)
Comorbidities (%)
HTN 93 (79) 22 (76) 71 (81) 0.58
DM 68 (58) 13 (45) 55 (63) 0.09
CKD 87 (74) 20 (69) 67 (76) 0.44
Chronic lung disease 27 (23) 5 (17) 22 (25) 0.39
Years from transplant 5.68 (2.09-9.9) 5.77 (2.35-9.69) 5.44 (2.09-10.55) 0.60
Baseline immunosuppression (%)
Calcineurin inhibitor 105 (90) 28 (97) 77 (88) 0.16
Mycophenolate 94 (80) 24 (83) 70 (80) 0.71
Steroids 71 (60) 22 (76) 49 (56) 0.04
Belatacept 8 (7) 1 (3) 7 (8) 0.40
Therapy
Hydroxychloroquine 94 (80) 26 (90) 68 (77) 0.20
Azithromycin 60 (51) 16 (55) 44 (50) 0.46
Remdesivir 8 (7) 1 (3) 7 (8) 0.40
High dose corticosteroids 43 (37) 22 (76) 21 (24) <0.01
Disease Severity
New dialysis requirement 13 (11) 10 (34) 3 (3) <0.01
Ever in ICU 36 (31) 18 (62) 18 (20) <0.01
Ever Intubated 34 (29) 18 (62) 16 (18) <0.01

Secondary Complications (%)

Venous thrombosis 8 (7) 5 (17) 3 (3) 0.02
Cerebrovascular events 3 (3) 3 (10) 0 (0) 0.004
Patients with infections 22 (19) 10 (34) 12 (14) 0.03
Infectious episodesb
 Blood stream infection 6 2c 4d
Bacterial pneumonia 6 3e 3f
C. difficile 2 1 1
Aspergillus 2 1 1
CMV 10 5 5
Peak CMV viral load, IU/mL 716 (193-1469) 1469 (1326-8994) 263 (193-418)
Other infections 3 2g 1h
Outcomes
Death 30 (26) 12 (41) 18 (20) 0.03
Hospital discharge 86 (74) 15 (52) 71 (81) 0.04
a
All continuous data presented as median (IQR)
b
Some patients experienced multiple infectious episodes
c
Candida glabrata, Klebsiella pneumonia
d
Streptococcus agalactiae, Stenotrophomonas maltophilia, Enterobacter cloacae complex, ESBL
Klebsiella pneumonia, Salmonella species
e
1 MRSA, 2 Pseudomonas aeruginosa
f
Stenotrophomonas maltophilia, Burkholderia cepacia complex, MRSA
g
HHV-6, EBV
h
Candida esophagitis